Should Diverging Views On AI Risks And CRM Strengths Require Action From Veeva Systems (VEEV) Investors?

• In recent months, several institutional investors highlighted Veeva Systems after strong recurring revenue growth and raised full-year guidance, even as its stock lagged amid a rotation away from higher-valuation healthcare technology names and caution around the timing of large enterprise deals.
• While some funds exited Veeva citing rising competitive and AI-related risks, others emphasized its leading life sciences CRM platform and expanding role across R&D and commercial data clouds, underscoring divided investor views on how these risks balance against its product strengths.
• Next, we’ll examine how these heightened competitive and AI-related concerns may influence Veeva Systems’ existing investment narrative and risk profile.

Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

Veeva Systems Investment Narrative Recap

To own Veeva Systems, you need to believe its core life sciences platforms can stay essential as the industry digitizes, even with intensifying AI and CRM competition. The key near term catalyst remains execution on AI embedded across Vault and CRM, while the biggest risk is that rivals use AI and broader suites to pressure Veeva’s “best of breed” edge. The recent fund exits and underperformance highlight that risk perception, but do not fundamentally change this core debate.

Against this backdrop, Veeva’s December 2025 launch of AI Agents for Vault CRM and PromoMats looks especially relevant. These tools sit squarely in the areas investors are debating, aiming to deepen Veeva’s role in customers’ daily workflows and potentially reinforce the catalyst around broader platform adoption. Whether these AI capabilities offset concerns about rising competition and deal timing will likely shape how the recent institutional repositioning is interpreted over time.

Yet beneath Veeva’s strong recurring revenue story, the growing competitive and AI related threats to its life sciences CRM franchise are something investors should be aware of...

Read the full narrative on Veeva Systems (it's free!)

Veeva Systems' narrative projects $4.3 billion revenue and $1.3 billion earnings by 2028. This requires 12.8% yearly revenue growth and an earnings increase of about $490 million from $809.9 million today.

Uncover how Veeva Systems' forecasts yield a $308.63 fair value, a 76% upside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts were assuming about 11.9% annual revenue growth and flat 27.9% margins before this news, which is far more pessimistic than the view that Veeva’s expanding Development Cloud and IQVIA enabled data integration could broaden its role despite recent stock pressure, reminding you that reasonable people can look at the same numbers and reach very different conclusions that may now need updating.

Explore 5 other fair value estimates on Veeva Systems - why the stock might be worth as much as 76% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Veeva Systems research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Veeva Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Veeva Systems' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com